LUCD vs. DCTH, TMCI, OM, NPCE, CLPT, NNOX, SKIN, ZIMV, BSGM, and SNWV
Should you be buying Lucid Diagnostics stock or one of its competitors? The main competitors of Lucid Diagnostics include Delcath Systems (DCTH), Treace Medical Concepts (TMCI), Outset Medical (OM), NeuroPace (NPCE), ClearPoint Neuro (CLPT), Nano-X Imaging (NNOX), Beauty Health (SKIN), ZimVie (ZIMV), Biosig Technologies (BSGM), and Sanuwave Health (SNWV). These companies are all part of the "medical equipment" industry.
Lucid Diagnostics vs. Its Competitors
Delcath Systems (NASDAQ:DCTH) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.
In the previous week, Delcath Systems and Delcath Systems both had 3 articles in the media. Lucid Diagnostics' average media sentiment score of 1.18 beat Delcath Systems' score of 0.65 indicating that Lucid Diagnostics is being referred to more favorably in the news media.
Delcath Systems presently has a consensus target price of $24.00, indicating a potential upside of 111.64%. Lucid Diagnostics has a consensus target price of $3.55, indicating a potential upside of 211.40%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Lucid Diagnostics is more favorable than Delcath Systems.
Delcath Systems has a net margin of -26.38% compared to Lucid Diagnostics' net margin of -1,699.86%. Lucid Diagnostics' return on equity of 0.00% beat Delcath Systems' return on equity.
Delcath Systems has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.
Delcath Systems has higher revenue and earnings than Lucid Diagnostics. Delcath Systems is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 17.4% of Delcath Systems shares are owned by company insiders. Comparatively, 6.8% of Lucid Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Lucid Diagnostics beats Delcath Systems on 9 of the 15 factors compared between the two stocks.
Get Lucid Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LUCD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lucid Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:LUCD) was last updated on 7/11/2025 by MarketBeat.com Staff
